Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...